Disc Medicine, Inc. Employee-related Liabilities, Current
Disc Medicine, Inc. (IRON) had Employee-related Liabilities, Current of $6.36 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:EmployeeRelatedLiabilitiesCurrent · last filed 2026-07-30
- 2026-06-30: Employee-related Liabilities, Current $6.36M.
- 2026-03-31: Employee-related Liabilities, Current $4.49M.
- 2025-12-31: Employee-related Liabilities, Current $12.64M.
- 2025-09-30: Employee-related Liabilities, Current $9.00M.
| Period end | Employee-related Liabilities, Current |
|---|---|
| 2026-06-30 | $6.36M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $4.49M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $12.64M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $9.00M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $4.15M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.81M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $7.21M 10-K · filed 2026-02-26 |
| 2024-09-30 | $4.57M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $3.49M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.16M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $5.79M 10-K · filed 2025-02-27 |
| 2023-09-30 | $3.17M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.12M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $876.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $3.62M 10-K · filed 2024-03-21 |
| 2021-12-31 | $1.18M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |